Morning Edition: Global drugmakers rush to boost US presence as tariff threat looms

Last updated: January 18, 2026 11:23 am

Mujeeb Osman 3 months ago

Chicago – January 18, 2026

Global drugmakers are ramping up U.S. manufacturing and stockpiling inventory as the Trump administration considers imposing a 100% tariff on imported branded and patented medicines.

Although enforcement is delayed for companies investing in U.S. manufacturing, the policy has already prompted fast-tracked projects, price cuts and direct-to-consumer sales.

Pfizer and AstraZeneca secured multi-year tariff exemptions through pricing deals and commitments to the new TrumpRx.gov platform. Eli Lilly, Johnson & Johnson and Merck have pledged billions to expand U.S. operations to avoid penalties.

TAGGED:USS Gerald R. Ford Crew Frustrated as Design Flaws Cause Ongoing Plumbing System Failures.

Share This Article

By Mujeeb Osman

With 26 years of journalism experience across Urdu and English newspapers, he has built a reputation for thoughtful, community-focused reporting. Mujeeb Osman previously served as the Chicago in-charge of The Muslim Observer, where he covered local, national, and international issues impacting diverse communities. At Chicago Patriot News, he continues his commitment to delivering accurate, balanced, and compelling stories. His work reflects a deep interest in immigration issues, public policy, and American politics, areas he has followed closely throughout his career. At Chicago Patriot News, he continues his commitment to delivering accurate, balanced, and compelling stories that illuminate the challenges and perspectives shaping today’s public discourse.